Currently, the forefront of optimism resides in medications designed to target FGFR2 fusion and IDH1/2 mutations as well as immunotherapy, offering a substantial promise for the advancement of future CCA management paradigms. The gene discussed is FGFR2; the disease is cholangiocarcinoma.